Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma

A novel serum microRNA panel to discriminate benign from malignant ovarian disease

(2015) Ream Langhe et al.   CANCER LETTERS

CpG signalling, H2A.Z/H3 acetylation and microRNA-mediated deferred self-attenuation orchestrate foetal NOS3 expression

(2015) Jan Postberg et al.   Clinical Epigenetics

Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation

(2014) Philippe Moreau et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

MicroRNAs in B-cell lymphomas: how a complex biology gets more complex

(2014) K Musilova et al.   LEUKEMIA

Ectopic MicroRNA-150-5p Transcription Sensitizes Glucocorticoid Therapy Response in MM1S Multiple Myeloma Cells but Fails to Overcome Hormone Therapy Resistance in MM1R Cells

(2014) Ajay Palagani et al.   PLoS One

Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen

(2014) Suraj Konnath George et al.   Translational Oncology

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma

(2014) Chonglei Bi et al.   Biomed Research International

MicroRNAs in Cancer

(2013) Gianpiero Di Leva et al.   Annual Review of Pathology-Mechanisms of Disease

Aberrant microRNA expression in multiple myeloma

(2013) Konstantinos Dimopoulos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory Activity

(2013) Yuriko Furuya et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MicroRNA theragnostics for the clinical management of multiple myeloma

(2013) N Ahmad et al.   LEUKEMIA

The MicroRNA-148/152 Family: Multi-faceted Players

(2013) Yue Chen et al.   Molecular Cancer

Adult-specific functions of animal microRNAs

(2013) Kailiang Sun et al.   NATURE REVIEWS GENETICS

LRP-6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK-1

(2013) Shuyu Ren et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma

(2012) P. Tagliaferri et al.   CURRENT CANCER DRUG TARGETS

Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype

(2012) A Rio-Machin et al.   LEUKEMIA

Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma

(2012) Victor H. Jimenez-Zepeda et al.   LEUKEMIA & LYMPHOMA

The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells

(2012) H. J. Landau et al.   MOLECULAR CANCER THERAPEUTICS

A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1

(2012) Qing Xu et al.   Journal of Molecular Cell Biology

Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1

(2011) Yi-Kun Zhang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

miR-152 Is a Tumor Suppressor microRNA That Is Silenced by DNA Hypermethylation in Endometrial Cancer

(2011) T. Tsuruta et al.   CANCER RESEARCH

MECHANISMS IN ENDOCRINOLOGY: Micro-RNAs: targets for enhancing osteoblast differentiation and bone formation

(2011) Hanna Taipaleenmäki et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

β-Catenin/LEF1 transactivates the microRNA-371-373 cluster that modulates the Wnt/β-catenin-signaling pathway

(2011) A-D Zhou et al.   ONCOGENE

A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study

(2010) S. Lonial et al.   CLINICAL CANCER RESEARCH

miR-29 Modulates Wnt Signaling in Human Osteoblasts through a Positive Feedback Loop

(2010) Kristina Kapinas et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

(2010) M A Dimopoulos et al.   LEUKEMIA

Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling

(2010) N C Gutiérrez et al.   LEUKEMIA

Lenalidomide for bortezomib-resistant multiple myeloma

(2010) Chiara Briani et al.   Nature Reviews Clinical Oncology

Small RNA sorting: matchmaking for Argonautes

(2010) Benjamin Czech et al.   NATURE REVIEWS GENETICS

miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expression

(2010) T Murata et al.   PROSTATE CANCER AND PROSTATIC DISEASES

MicroRNAs, macrocontrol: Regulation of miRNA processing

(2010) I. Slezak-Prochazka et al.   RNA

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

(2009) M. Fulciniti et al.   BLOOD

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

(2009) Y. Zheng et al.   BLOOD

Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas

(2009) Eri Hiroki et al.   CANCER SCIENCE

Stem cell transplantation for multiple myeloma

(2009) Shaji Kumar   CURRENT OPINION IN ONCOLOGY

Many roads to maturity: microRNA biogenesis pathways and their regulation

(2009) Julia Winter et al.   NATURE CELL BIOLOGY

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma

(2007) Ya-Wei Qiang et al.   BONE